menu
    • menu
    [{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"Simcere Zaiming","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Deulorlatinib","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen TargetRx \/ Simcere Zaiming","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen TargetRx \/ Simcere Zaiming"}]

    Find Clinical Drug Pipeline Developments & Deals by Shenzhen TargetRx

    Menu

    Shenzhen TargetRx

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Shenzhen TargetRx

                            China arrow
                            Interphex
                            Not Confirmed

                            Shenzhen TargetRx

                            China arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deulorlatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Simcere Zaiming

                            Deal Size : $20.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Simcere Zaiming Collaborates with TargetRx to Introduce a Third-Generation ALK inhibitor

                            Details :

                            Product Name : TGRX-326

                            Product Type : Other Small Molecule

                            Upfront Cash : $20.0 million

                            February 09, 2024

                            Lead Product(s) : Deulorlatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Simcere Zaiming

                            Deal Size : $20.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth